Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical roundtable monograph: Unmet needs in the management of chronic myelogenous leukemia.

Clinical advances in hematology & oncology : H&O - 1 Dec 2012

Jabbour Elias J, Bixby Dale, Akard Luke P

Abstract excerpt

Approximately 5,000 cases of chronic myelogenous leukemia (CML) are diagnosed each year in the United States. The introduction of tyrosine kinase inhibitors (TKIs) has dramatically improved survival time for many CML patients. Current first-line treatment options include imatinib and the second-generation agents nilotinib and dasatinib. Second- and third-line agents include nilotinib, dasatinib, bosutinib, and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BCR gene
Share to Fusion Proteins, bcr-abl
Share to Hematopoietic Stem Cell Transplantation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Mutation

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 23271195

Genes

BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical roundtable monograph: Unmet needs in the management of chronic myelogenous leukemia.PMID 23271195Read ↗

A review of the European LeukemiaNet recommendations for the management of CML.Semantic proximity Read ↗

Optimizing second-line therapy for chronic myeloid leukemia.Semantic proximity Read ↗

Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and managementSemantic proximity Read ↗

Treatment and molecular monitoring update in chronic myeloid leukemia management.Semantic proximity Read ↗

Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and managementSemantic proximity Read ↗

Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in OncologySemantic proximity Read ↗

Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoringSemantic proximity Read ↗

[Recommendations from the GBMHM and the Fi-LMC for the diagnosis and management of chronic myeloid leukemia].Semantic proximity Read ↗

Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoringSemantic proximity Read ↗

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.Semantic proximity Read ↗

Treatment of chronic myelogenous leukemia.Semantic proximity Read ↗

Monitoring response to tyrosine kinase inhibitor therapy, mutational analysis, and new treatment options in chronic myelogenous leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.